A Single Dose Study of Debio 1450 in Healthy Subjects

Debiopharm

Status and phase

Completed

Phase 1

Conditions

Bacterial Infections

Treatments

Drug: Placebo

Drug: Debio 1450

Study type

Interventional

Funder types

Industry

Identifiers

NCT02162199

Debio 1450-102

217596 (Other Identifier)

Details and patient eligibility

About

The sponsor is trying to develop a medicine for infections that are not cured by regular antibiotics. They have an experimental drug called Debio 1450 that may work. They need about 48 healthy adults to volunteer for this study.

This study looks at what the body does to the drug. It measures how the amount of drug in blood and urine changes over time.

From the screening visit through the follow-up visit may be up to 40 days. Volunteers go to the clinic in Baltimore for a screening visit. The study doctor chooses qualified volunteers to participate or serve as alternates. Alternates might not actually complete the study procedures.

The study doctor divides participants into groups of eight. Six receive Debio 1450 and 2 receive Placebo. The drug each participant receives is decided by chance - like flipping a coin.

Eligible volunteers check into the clinic for testing and those chosen to participate remain for a 5-day/ 4-night stay. The clinic serves standard meals, except when fasting is required. Participants must stay at the clinic for the length of the study.

This study is a "dose escalation" study. That means that if no safety concerns come up a new group starts. Each new group of eight participants receives more capsules.

The study product is contained in capsules. Each capsule contains either placebo or 40 mg Debio 1450. After fasting overnight, the first two participants in the group receive their capsules. One gets Debio 1450 and one gets Placebo. If these participants tolerate side effects for 24 hours, the remaining six participants receive their assigned capsules.

The plan is to increase the dose for the next group. The study doctor reviews the measurements collected from each group after three days. He may decide to repeat, increase, or lower the dose or even stop the study. The most any participant receives is 800 mg in 20 capsules.

Enrollment

48 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Is a healthy adult
Has met protocol-specified criteria for qualification and use of contraception
Is willing and able to remain confined in the study unit for the entire duration of the treatment period and comply with restrictions related to food, drink and medications
Has voluntarily consented to participate and provided written informed consent prior to any protocol-specific procedures

Exclusion criteria

Has screening laboratory values outside protocol-specified limits
Has history of a clinically significant allergic drug reaction
Has donated a volume of plasma or whole blood within a time frame not allowed per protocol
Has historical or current use not allowed per protocol of:
1. over-the-counter medications
2. certain foods; dietary, mineral or herbal supplements
3. licit or illicit drugs (including experimental drugs, caffeine, nicotine and alcohol)
Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
1. the safety or well-being of the participant or study staff
2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
3. the analysis of results